The evaluation of the plasma levels of interleukin 17A, thymic stromal lymphopoietin, interferon gamma, tumor necrosis factor-alpha and interleukins IL-2, IL-6, IL-23, and IL-31 in atopic dermatitis patients with dupilumab treatment. [PDF]
Čelakovská J +3 more
europepmc +1 more source
Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies. [PDF]
Kwatra SG +9 more
europepmc +1 more source
European S2k guidelines on management of autoimmune blistering diseases in children and adolescents
Autoimmune blistering disorders (AIBDs) in children are rare, challenging to diagnose and treat and often require immunosuppressants. Until now, no paediatric care guidelines existed. The EADV Task Force for AIBDs has developed the consensus‐based recommendations, enabling physicians to adopt a uniform, tailored treatment strategy to improve outcomes ...
A. Nanda +31 more
wiley +1 more source
Dupilumab in patients with cold urticaria: Results from a phase 3 trial. [PDF]
Metz M +9 more
europepmc +1 more source
Effective Management of Recalcitrant Hailey–Hailey Disease With Risankizumab
International Journal of Dermatology, EarlyView.
Joy Justice +3 more
wiley +1 more source
This analysis used a large clinical trial data set (>30,000 patient visits across >2800 patients) and novel statistical methodologies (including frequency cross‐over analysis and means based on spline regression) to develop severity threshold bands for clinician‐ and patient‐reported outcome measures for adults with moderate‐to‐severe atopic dermatitis.
Andreas Wollenberg +7 more
wiley +1 more source
Matching-adjusted indirect comparison analysis of omalizumab versus dupilumab in patients with chronic spontaneous urticaria. [PDF]
Mosnaim G +4 more
europepmc +1 more source
Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger +11 more
wiley +1 more source
Dupilumab for Atopic Dermatitis-Associated Nail Dystrophy: A Case Report. [PDF]
Zhao Z, Li H, Luo D, Guan L, Yang F.
europepmc +1 more source
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema Questionnaire
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Eric L. Simpson +10 more
wiley +1 more source

